Theoretical studies on farnesyltransferase: The distances paradox explained

In spite of the enormous interest that has been devoted to its study, the mechanism of the enzyme farnesyltransferase (FTase) remains the subject of several crucial doubts. In this article, we shed a new light in one of the most fundamental dilemmas that characterize the mechanism of this puzzling enzyme commonly referred to as the “distances paradox”, which arises from the existence of a large 8‐Å distance between the two reactive atoms in the reaction catalyzed by this enzyme: a Zn‐bound cysteine sulphur atom from a peptidic substrate and the farnesyldiphosphate (FPP) carbon 1. This distance must be overcome for the reaction to occur. In this study, the two possible alternatives were evaluated by combining molecular mechanics (AMBER) and quantum chemical calculations (B3LYP). Basically, our results have shown that an activation of the Zn‐bound cysteine thiolate with subsequent displacement from the zinc coordination sphere towards the FPP carbon 1 is not a realistic hypothesis of overcoming the large distance reported in the crystallographic structures of the ternary complexes between the two reactive atoms, but that a rotation involving the FPP molecule can bring the two atoms closer with moderate energetic cost, coherent with previous experimental data. This conclusion opens the door to an understanding of the chemical step in the farnesylation reaction. Proteins 2007. © 2006 Wiley‐Liss, Inc.

[1]  David K Williams,et al.  Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. , 2005, Journal of medicinal chemistry.

[2]  S. Sebti,et al.  Inhibitors of protein farnesyltransferase as novel anticancer agents. , 2002, Current Topics in Medicinal Chemistry.

[3]  Thom Vreven,et al.  Model studies of the structures, reacitivities, and reaction mechanisms of metalloenzymes , 2001, IBM J. Res. Dev..

[4]  S. Johnston,et al.  Protein farnesyltransferase inhibitors , 2003, Expert opinion on emerging drugs.

[5]  P. Cassidy,et al.  Yeast protein farnesyltransferase: steady-state kinetic studies of substrate binding. , 1995, Biochemistry.

[6]  P. Rathod,et al.  Resistance to a Protein Farnesyltransferase Inhibitor in Plasmodium falciparum* , 2005, Journal of Biological Chemistry.

[7]  G. Klebe,et al.  Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi. , 2005, Journal of medicinal chemistry.

[8]  J. Stewart.  Optimization of parameters for semiempirical methods II. Applications , 1989 .

[9]  M. Gelb,et al.  Mammalian protein geranylgeranyltransferase-I: substrate specificity, kinetic mechanism, metal requirements, and affinity labeling. , 1995, Biochemistry.

[10]  T. Ziegler.  Approximate Density Functional Theory as a Practical Tool in Molecular Energetics and Dynamics , 1991 .

[11]  C. Marshall,et al.  All ras proteins are polyisoprenylated but only some are palmitoylated , 1989, Cell.

[12]  Zhanghua Wu,et al.  Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. , 1998, Biochemistry.

[13]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.

[14]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[15]  G. Klebe,et al.  Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity. , 2005, European journal of medicinal chemistry.

[16]  Pedro Alexandrino Fernandes,et al.  Theoretical studies on the mechanism of inhibition of Ribonucleotide Reductase by (E)-2'-Fluoromethylene-2'-deoxycitidine-5'-diphosphate. , 2003, Journal of the American Chemical Society.

[17]  C. Poulter,et al.  A mechanism for posttranslational modifications of proteins by yeast protein farnesyltransferase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Moores,et al.  Sequence dependence of protein isoprenylation. , 1991, The Journal of biological chemistry.

[19]  U. Ryde,et al.  Carboxylate binding modes in zinc proteins: a theoretical study. , 1999, Biophysical journal.

[20]  P. Fernandes,et al.  Theoretical insights into the mechanism for thiol/disulfide exchange. , 2004, Chemistry.

[21]  Margareta R. A. Blomberg,et al.  Modeling Electron Transfer in Biochemistry: A Quantum Chemical Study of Charge Separation in Rhodobacter sphaeroides and Photosystem II , 1998 .

[22]  Jacopo Tomasi,et al.  Continuum solvation models: A new approach to the problem of solute’s charge distribution and cavity boundaries , 1997 .

[23]  C. Fierke,et al.  Lysine β311 of Protein Geranylgeranyltransferase Type I Partially Replaces Magnesium* , 2004, Journal of Biological Chemistry.

[24]  Charles W. Bauschlicher,et al.  A comparison of the accuracy of different functionals , 1995 .

[25]  Michael Dolg,et al.  Energy‐adjusted ab initio pseudopotentials for the first row transition elements , 1987 .

[26]  P. Casey,et al.  The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures. , 2000, Structure.

[27]  M. Gelb,et al.  The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. , 2005, Journal of medicinal chemistry.

[28]  H. Stoll,et al.  Energy-adjustedab initio pseudopotentials for the second and third row transition elements , 1990 .

[29]  S. Hahn,et al.  Farnesyltransferase inhibitors. , 2001, Seminars in oncology.

[30]  F. Caponigro,et al.  Farnesyl transferase inhibitors in clinical development , 2003, Expert opinion on investigational drugs.

[31]  Leif A. Eriksson,et al.  The reduction of ribonucleotides catalyzed by the enzyme ribonucleotide reductase , 2002 .

[32]  P. Casey,et al.  Kinetic analysis of zinc ligand mutants of mammalian protein farnesyltransferase. , 1998, Biochemistry.

[33]  W. R. Bishop,et al.  Farnesyltransferase inhibitors as anticancer agents: critical crossroads. , 2004, Current opinion in drug discovery & development.

[34]  M. Gelb,et al.  Cloning, Heterologous Expression, and Distinct Substrate Specificity of Protein Farnesyltransferase from Trypanosoma brucei * , 2000, The Journal of Biological Chemistry.

[35]  J. Rizo,et al.  Conformation of a heptapeptide substrate bound to protein farnesyltransferase. , 1993, Biochemistry.

[36]  Sérgio F. Sousa,et al.  Farnesyltransferase: Theoretical studies on peptide substrate entrance—thiol or thiolate coordination? , 2005 .

[37]  A. Becke.  Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[38]  D. Chakrabarti,et al.  Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. , 2005, Angewandte Chemie.

[39]  Stephen B. Long,et al.  Reaction path of protein farnesyltransferase at atomic resolution , 2002, Nature.

[40]  K. Kaibuchi,et al.  Small GTP-binding proteins. , 1992, International review of cytology.

[41]  Crowther,et al.  Protein farnesyltransferase: structure and implications for substrate binding , 1998, Biochemistry.

[42]  M. Brown,et al.  Cloning and expression of a cDNA encoding the alpha subunit of rat p21ras protein farnesyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Croft,et al.  Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. , 2004, Journal of medicinal chemistry.

[44]  R. Muschel,et al.  Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. , 2003, Cancer research.

[45]  G. Klebe,et al.  Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. , 2004, Angewandte Chemie.

[46]  J. Schellens,et al.  Development of farnesyl transferase inhibitors: a review. , 2005, The oncologist.

[47]  K. Morokuma,et al.  A NEW ONIOM IMPLEMENTATION IN GAUSSIAN98. PART I. THE CALCULATION OF ENERGIES, GRADIENTS, VIBRATIONAL FREQUENCIES AND ELECTRIC FIELD DERIVATIVES , 1999 .

[48]  P. Casey,et al.  Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation. , 2003, Biochemistry.

[49]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[50]  J. Stewart.  Optimization of parameters for semiempirical methods I. Method , 1989 .

[51]  C. Fierke,et al.  Mutagenesis Studies of Protein Farnesyltransferase Implicate Aspartate β352 as a Magnesium Ligand* , 2003, Journal of Biological Chemistry.

[52]  Zhengliang L. Wu,et al.  Farnesyl protein transferase: Identification of K164α and Y300β as catalytic residues by mutagenesis and kinetic studies , 1999 .

[53]  L. Gierasch,et al.  Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. , 1991, The Journal of biological chemistry.

[54]  Pedro Alexandrino Fernandes,et al.  Theoretical studies on the mode of inhibition of ribonucleotide reductase by 2'-substituted substrate analogues. , 2003, Chemistry.

[55]  Per E. M. Siegbahn,et al.  Theoretical Study of the Substrate Mechanism of Ribonucleotide Reductase , 1998 .

[56]  Walter Thiel,et al.  Enzymatic reactions of triosephosphate isomerase: A theoretical calibration study , 2002 .

[57]  P. Casey,et al.  Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. , 1998, Biochemistry.

[58]  J. Shafer,et al.  Isoprenoid diphosphate utilization by recombinant human farnesyl:protein transferase: interactive binding between substrates and a preferred kinetic pathway. , 1993, Biochemistry.

[59]  C. Poulter,et al.  Yeast protein farnesyltransferase. Site-directed mutagenesis of conserved residues in the beta-subunit. , 1997, Biochemistry.

[60]  S. Armstrong,et al.  Nonidentical subunits of p21H-ras farnesyltransferase. Peptide binding and farnesyl pyrophosphate carrier functions. , 1991, The Journal of biological chemistry.

[61]  Sérgio F. Sousa,et al.  Effective tailor-made force field parameterization of the several Zn coordination environments in the puzzling FTase enzyme: opening the door to the full understanding of its elusive catalytic mechanism , 2006 .

[62]  C. Fierke,et al.  Structural characterization of the zinc site in protein farnesyltransferase. , 2003, Journal of the American Chemical Society.

[63]  H. Hellinga,et al.  The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Chia‐Yu Huang,et al.  Farnesyltransferase inhibitors: recent advances , 2004 .

[65]  Wolfram Koch,et al.  The performance of density functional/Hartree-Fock hybrid methods: the bonding in cationic first-row transition metal methylene complexes , 1995 .

[66]  J. Tomasi,et al.  Ab initio study of ionic solutions by a polarizable continuum dielectric model , 1998 .

[67]  Jacopo Tomasi,et al.  A new integral equation formalism for the polarizable continuum model: Theoretical background and applications to isotropic and anisotropic dielectrics , 1997 .

[68]  M. Bogusky,et al.  NMR studies of novel inhibitors bound to farnesyl‐protein transferase , 1995, Protein science : a publication of the Protein Society.

[69]  C. Poulter,et al.  Yeast protein farnesyltransferase. pKas of peptide substrates bound as zinc thiolates. , 1999, Biochemistry.

[70]  P. Myler,et al.  Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. , 2002, Molecular and biochemical parasitology.

[71]  Michael S. Brown,et al.  Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P. Gerold,et al.  Identification and characterisation of Toxoplasma gondii protein farnesyltransferase. , 2001, International journal for parasitology.

[73]  M. Brown,et al.  Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Maria João Ramos,et al.  Farnesyltransferase--new insights into the zinc-coordination sphere paradigm: evidence for a carboxylate-shift mechanism. , 2005, Biophysical journal.

[75]  D. Russell,et al.  cDNA cloning and expression of the peptide-binding β subunit of rat p21rasfarnesyltransferase, the counterpart of yeast DPR1/RAM1 , 1991, Cell.

[76]  C. Der,et al.  Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Mayuso Kuno,et al.  Theoretical investigation on nevirapine and HIV-1 reverse transcriptase binding site interaction, based on ONIOM method , 2003 .

[78]  K. Morokuma,et al.  On the application of the IMOMO (integrated molecular orbital + molecular orbital) method , 2000 .

[79]  J. Stewart.  Optimization of parameters for semiempirical methods. III Extension of PM3 to Be, Mg, Zn, Ga, Ge, As, Se, Cd, In, Sn, Sb, Te, Hg, Tl, Pb, and Bi , 1991 .

[80]  P. Casey,et al.  Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides , 1990, Cell.

[81]  Wely B. Floriano,et al.  Theoretical study of arginine-carboxylate interactions , 1999 .

[82]  R. Diehl,et al.  Mutational Analysis of Conserved Residues of the β-Subunit of Human Farnesyl:Protein Transferase* , 1997, The Journal of Biological Chemistry.

[83]  Per E M Siegbahn,et al.  Catalytic mechanism of matrix metalloproteinases: two-layered ONIOM study. , 2002, Inorganic chemistry.

[84]  W. Schafer,et al.  Protein prenylation: genes, enzymes, targets, and functions. , 1992, Annual review of genetics.

[85]  K. Morokuma,et al.  Effects of the protein environment on the structure and energetics of active sites of metalloenzymes. ONIOM study of methane monooxygenase and ribonucleotide reductase. , 2002, Journal of the American Chemical Society.

[86]  Giovanni Scalmani,et al.  New developments in the polarizable continuum model for quantum mechanical and classical calculations on molecules in solution , 2002 .

[87]  Pedro Alexandrino Fernandes,et al.  Unraveling the mechanism of the farnesyltransferase enzyme , 2004, JBIC Journal of Biological Inorganic Chemistry.

[88]  C. Der,et al.  Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Ping Liu,et al.  In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. , 2003, The Journal of clinical investigation.

[90]  D. Chakrabarti,et al.  Protein Farnesyltransferase and Protein Prenylation inPlasmodium falciparum * , 2002, The Journal of Biological Chemistry.

[91]  P. Casey,et al.  Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. , 1995, Biochemistry.

[92]  C. Bauschlicher,et al.  A comparison of density functional theory withab initio approaches for systems involving first transition row metals , 1995 .

[93]  C. Farnsworth,et al.  Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. , 1994, Annual review of cell biology.

[94]  Pedro Alexandrino Fernandes,et al.  Theoretical study of ribonucleotide reductase mechanism‐based inhibition by 2′‐azido‐2′‐deoxyribonucleoside 5′‐diphosphates , 2004, J. Comput. Chem..

[95]  Giovanni Scalmani,et al.  Energies, structures, and electronic properties of molecules in solution with the C‐PCM solvation model , 2003, J. Comput. Chem..

[96]  Leif A. Eriksson,et al.  Hydrogen Atom Transfer in Ribonucleotide Reductase (RNR) , 1998 .

[97]  G. Frenking,et al.  Pseudopotential Calculations of Transition Metal Compounds: Scope and Limitations , 2007 .